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Abstract 
Background: Adult T-cell leukemia (ATL) is caused by human T-cell leukemia virus type 1 (HTLV-1) infection. However, 
there are no therapies to prevent ATL development in high-risk asymptomatic carriers. To develop a therapy targeting 
HTLV-1-infected cells that are known to express CCR4 frequently, we tested whether truncated Pseudomonas exotoxin 
(PE38) fused to a CCR4 ligand, CCL17/thymus and activation-regulated chemokine (TARC), selectively eliminates such 
cells.
Results: Our data show that TARC–PE38 efficiently killed HTLV-1-infected cell lines. It also shrank HTLV-1-associated 
solid tumors in an infected-cell-engrafted mouse model. In HTLV-1-positive humanized mice, TARC–PE38 mark-
edly inhibited the proliferation of HTLV-1-infected human CD4+CD25+ or CD4+CD25+CCR4+ cells and reduced the 
proviral loads (PVLs) in peripheral blood mononuclear cells (PBMCs). Importantly, TARC–PE38 significantly reduced 
the PVLs in PBMCs obtained from asymptomatic carriers. We show that the cytotoxicity of TARC–PE38 is mediated by 
the expression of the proprotein convertase, furin. The expression of furin was enhanced in HTLV-1-infected cells and 
correlated positively with PVLs in HTLV-1-infected individuals, suggesting that infected cells are more susceptible to 
TARC–PE38 than normal cells.
Conclusions: TARC–PE38 robustly controls HTLV-1 infection by eliminating infected cells in both a CCR4- and furin-
dependent manner, indicating the excellent therapeutic potential of TARC–PE38.
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Background
Human T-cell leukemia virus type 1 (HTLV-1) is a human 
retrovirus that causes HTLV-1-related diseases, includ-
ing adult T-cell leukemia (ATL) [1–5]. ATL develops in 
asymptomatic carriers of HTLV-1 after latent infection 
for at least 20–30  years, with an estimated lifetime risk 
of 6–7 % for males and 2–3 % for females [6]. A recent 
national survey in Japan reported at least one million 
eighty thousand asymptomatic carriers [7]. Although 
several anti-ATL therapies are available, including 
chemotherapy [8, 9], ATL is often resistant to these and 
its prognosis remains poor [10, 11]. The Joint Study on 
Predisposing Factors of ATL Development (JSPFAD) 
[12] showed that asymptomatic carriers with a proviral 
load (PVL) exceeding 4 % (copies/100 cells) constitute a 
high-risk group in whom ATL selectively develops [13]. 
Therefore, active interventions, including a prophylactic 
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therapy, are urgently required to prevent the progression 
to ATL in this high-risk group.
Thymus and activation-regulated chemokine (TARC)/
CCL17 and macrophage-derived chemokine (MDC)/
CCL22 share CC chemokine receptor 4 (CCR4), which 
is predominantly expressed on type 2 helper T cells 
and regulatory T cells (Tregs) [14–17]. Recent studies 
have demonstrated that CCR4 is frequently expressed 
in HTLV-1-infected cells, which are predominantly 
CD4+CD25+ [18–21]. The expression of MDC is also 
induced by the HTLV-1 transactivator protein, Tax, in 
infected cells [22]. The induced MDC seems to attract 
normal CCR4+ T-cells, resulting in the preferential infec-
tion of these cells [22] via cell-to-cell contact [23], and 
maintain a high frequency of functional CCR4+FoxP3+ 
Tregs [24].
Recently, a defucosylated humanized anti-CCR4 mono-
clonal antibody (mAb), mogamulizumab, was developed 
as an anti-ATL drug [25–30]. This drug specifically binds 
to CCR4 on ATL cells and exerts antibody-dependent 
cellular cytotoxicity (ADCC) against the cells by binding 
to the Fc receptor (FcR) on NK cells. However, although 
this therapy is effective [30], severe adverse events have 
been reported [31–33].
In this study, we developed a candidate anti-HTLV-1 
therapeutic agent targeting CCR4, with a mode of action 
that differs from that of mogamulizumab. Our novel 
agent is TARC-fused truncated 38-kDa Pseudomonas 
aeruginosa exotoxin A (PE38) in which the CD91-bind-
ing domain is deleted, designated TARC–PE38 [34]. 
Full-length PE is known to elicit a cytotoxic effect that is 
dependent on the intracellular expression of the propro-
tein convertase, furin [35, 36], when it moves into cells 
by endocytosis after specifically binding to CD91 on the 
cell surface via its CD91-binding domain [37, 38]. How-
ever, when the CD91-binding domain of PE is switched 
for another protein-binding domain, the chimeric pro-
tein shows a new targeting specificity, dependent on the 
properties of the switched protein. Thus, TARC–PE38 is 
expected to specifically bind to CCR4 on target cells via 
its TARC domain and to exert similar cytotoxic effects 
on CCR4+ cells alone, in a furin-dependent manner. This 
therapeutic effect on HTLV-1-infected CCR4+ cells was 
tested in vitro and in vivo to determine the drug potential 
of TARC–PE38 in reducing the risk of ATL development 
in high-risk asymptomatic carriers.
Results
Elimination of HTLV‑1‑infected CCR4+ cells by TARC–PE38
Our previous study showed that TARC-PE38 effectively 
killed HTLV-1-negative CCR4-expressing T cells, CCRF-
CEM, through the apoptosis in  vitro and eliminated 
tumors using this cell line in model mice (in vivo) by the 
injections subcutaneously and intravenously [34].
In this study, HTLV-1-infected S1T, TL-Om1, MT-2, 
and HUT-102 cells were tested to examine the effect of 
TARC-PE38 on them. These cells were first analyzed with 
flow cytometry to confirm their cell-surface expression 
of CCR4 (Fig.  1a). As controls, HTLV-1-uninfected Jur-
kat, Raji, U937, and THP-1 cells were examined in paral-
lel. As expected, the S1T, TL-Om1, MT-2, and HUT-102 
cells expressed CCR4 with the mean fluorescence inten-
sity (MFI) of 332.9, 49.6, 197.7, and 27.8, respectively. The 
Jurkat cells expressed CCR4 at a lower level (MFI: 26.8) 
and the Raji, U937, and THP-1 cells expressed no CCR4.
Therefore, we tested the killing effect of TARC–PE38 
(10 or 20 μg/ml) on these cells (Fig. 1b). The TARC-fused 
oncofetal antigen (TARC–OFA; 10 or 20  μg/ml) and 
phosphate-buffered saline (PBS) were used as controls. 
Whereas TARC–OFA and PBS did not kill any of the cells 
tested, TARC–PE38 killed the S1T, TL-Om1, MT-2, and 
HUT-102 cells efficiently, and the Jurkat cells much less 
effectively. TARC–PE38 killed no Raji, U937, and THP-1 
cells, consistent with their lack of CCR4 expression.
We also examined whether either TARC–PE38 or 
TARC–OFA (control) killed the same cells in a dose-
dependent manner (0–20 μg/ml) (Fig.  1c). Surprisingly, 
TARC–PE38 killed the S1T cells completely, even at the 
lowest dose (5  μg/ml), probably because they have the 
highest cell-surface expression (MFI) of CCR4. TARC–
PE38 killed the TL-Om1, MT-2, and HUT-102 cells in a 
dose-dependent manner. However, even when the dose 
was increased to 20 μg/ml, the killing effect of TARC–
PE38 was only modestly enhanced in the Jurkat cells and 
not at all in the Raji, U937, and THP-1 cells. TARC–OFA 
killed none of the cells at any dose tested.
As demonstrated by flow cytometry, the HUT-102 
cells expressed CCR4 at a similar MFI to the Jurkat cells 
(27.8 vs 26.8, respectively), but most whole HUT-102 
cells expressed CCR4 like the TL-Om1 cells (almost 
100% positive) and unlike the Jurkat cells (lower % posi-
tive) (Fig. 1a). Thus, when TARC–PE38 was added to the 
HUT-102 cells, TARC–PE38 killed the cells more effec-
tively than it killed the Jurkat cells (Fig. 1b, c).
In addition, to rule out nonspecific effects of PE38, we 
examined whether PE38 alone (no protein fused to PE38) 
killed CCR4+ S1T cells in parallel with PBS. PE38 alone 
(20 μg/ml) as well as PBS did not kill the S1T cells at all 
(Fig.  1d). Thus, as neither TARC-OFA, PBS, nor PE-38 
alone killed any cells tested, PBS alone was used as a neg-
ative control in the following experiments.
Therefore, TARC–PE38 targets CCR4+ cells and exerts 
a cytotoxic effect on HTLV-1-infected cells in  vitro, at 
least in a CCR4-expression-dependent manner.
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Fig. 1 Elimination of HTLV-1-infected cell lines by TARC–PE38. a HTLV-1-infected S1T, TL-Om1, MT-2, and HUT-102 cells and uninfected Jurkat, Raji, 
U937, and THP-1 cells were tested for their expression of CCR4 with flow cytometry without (solid red line) or with an anti-CCR4 antibody (solid line 
filled with black). MFI, mean fluorescence intensity. b To examine the killing effects of TARC–PE38 on the cells described above, the numbers of live 
cells were counted daily for 5 days after either 10 or 20 μg/ml TARC–PE38 (closed triangles), 10 or 20 μg/ml TARC–OFA (open circles), or PBS (closed 
circles) was added to each cell line. The data are expressed as means ± SD (×105/ml). c To further determine the cytotoxicity of TARC–PE38 in the cells 
described above, each cell line was incubated with either TARC–PE38 (closed triangles) or TARC–OFA (open circles) at doses of 0 (PBS only added), 5, 10, 
or 20 μg/ml for 5 days, and the numbers of live cells were then counted. The data are expressed as means ± SD (×105/ml). d To rule out nonspecific 
effects of PE38, either PBS (closed circles) or 20 μg/ml PE38 alone (closed triangles) was added to S1T cells. Then the numbers of live cells were counted 
daily for 5 days, and the data are expressed as means ± SD (×105/ml). These results are representative of four independent experiments
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Regressive effect of TARC–PE38 on HTLV‑1‑associated 
tumor in a mouse model
Next, to examine the in  vivo effects of TARC–PE38, 
we constructed an HTLV-1-associated tumor-bearing 
mouse model. Because HTLV-1-infected HUT-102 cells 
are known to form tumors in immunodeficient mice 
most efficiently among cells tested [39], this cell line was 
selected to generate this model.
In a tumor-bearing mouse model with the HUT-102 
cells, TARC–PE38 had a striking regressive effect on 
the mass of the solid tumors in five mice treated with 
TARC–PE38 compared with five mice treated with PBS 
(Fig. 2a, b). The weights of the tumors were more strongly 
reduced by treatment with TARC–PE38 (mean final 
weight ~0.1  g) than by treatment with PBS (mean final 
weight ~0.6 g), and the difference in weight between the 
groups was statistically significant (p < 0.0001; Fig. 2c).
Therefore, TARC–PE38 efficiently inhibits tumor 
growth in an HTLV-1-associated tumor-bearing mouse 
model.
Therapeutic effect of TARC–PE38 on HTLV‑1 infection 
in humanized mice
To further confirm the in  vivo efficacy of TARC-PE38 
against HTLV-1, we constructed six HTLV-1-infected 
and three uninfected, humanized mice. Fourteen days 
after infection with mitomycin C (MMC)-treated MT-2 
cells, we used flow cytometry and quantitative PCR to 
confirm that no residual MT-2 cells were present in the 
infected mice (Additional file  1: Figure S1, Additional 
file 2: Figure S2, Additional file 3: Table S1). As shown in 
Fig.  3a, either 10 μg of TARC–PE38 per mouse or PBS 
(control) was administered to three of the six infected 
mice once a day on days 14–17. All the mice were bled on 
days 0, 14, 21, 28, and later, and peripheral blood mono-
nuclear cells (PBMCs) were then isolated from the blood.
Using flow cytometry, we tested the frequency of 
human HTLV-1-infected CD4+CD25+ cells in human 
CD45+ cells of the PBMCs (Fig. 3b, c). Because binding 
of TARC to CCR4 on cells induces internalization (down-





























Fig. 2 Antitumor effect of TARC–PE38 in a mouse model bearing an HTLV-1-related tumor. a HUT-102 cells (2 × 107 cells/mouse) were transplanted 
into the postauricular regions of 10 NOG mice. Either 25 μg/mouse TARC–PE38 or PBS was then administered to the same region once a day on 
days 1–5 after transplantation (a total of five times). The mice were observed and sacrificed on day 14 after transplantation to assess the therapeutic 
effect of TARC–PE38 on the solid tumors grown in the same region. The sizes of the tumors were compared among the mice sacrificed. Representa-
tive tumors of mice treated with PBS or TARC–PE38 were photographed with a standard digital camera. The tumors are surrounded by wavy lines. 
b All tumors grown in mice treated with PBS (n = 5, upper line) or TARC–PE38 (n = 5, lower line) were excised from the mice, compared, and photo-
graphed in the same way. The white bar represents 1 cm. c Tumors excised from mice treated with PBS (n = 5, closed circles) or TARC–PE38 (n = 5, 
closed triangles) were all weighed (in grams, g), and compared statistically (p < 0.0001). Bar represents the mean. These data are representative of 
more than two independent experiments
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Fig. 3 Antiviral effect of TARC–PE38 on HTLV-1 infection in humanized mice. a CD34+ HSCs were purified from human cord blood and transplanted 
intrahepatically into newly born NOJ mice. After these mice were humanized, nine mice were inoculated intraperitoneally without (n = 3, PBS only) 
or with MT-2 cells treated with MMC (n = 6) (day 0). Two weeks later, either 10 μg of TARC–PE38 or PBS was administered to the HTLV-1-infected 
mice (three mice in each group) intravenously once a day for four successive days (days 14–17). All mice were observed for more than 2 weeks after 
the administration of TARC–PE38 or PBS, and bled on days 0, 14, 21, 28, and later. b To assess the therapeutic effect of TARC–PE38 on HTLV-1-in-
fected cells, peripheral blood was obtained from all the mice described above. The PBMCs were isolated and the frequency of human CD4+CD25+ 
cells was determined with flow cytometry. The data are representative of each group as follows: none, uninfected untreated mice; MT-2 + PBS, 
HTLV-1-infected mice treated with PBS; MT-2 + TARC–PE38, HTLV-1-infected mice treated with TARC–PE38. The number indicated in the upper right 
quadrant is the frequency of human CD4+CD25+ cells (%). c The frequencies of human CD4+CD25+ cells (%) on the indicated days after infection 
are plotted for each mouse group: none (open circles), MT-2 + PBS (closed circles), or MT-2 + TARC-PE38 (closed triangles). The data are expressed 
as means ± SD (%). d To determine the effect of TARC-PE38 on CD4+CD25+ or CD4+CD25+CCR4+ cells, PBMCs obtained from each mouse group 
(MT-2 + PBS or MT-2 + TARC-PE38) after day 28 were checked for the frequency of human CD4+CD25+ cells (left panels) or CD4+CD25+CCR4+ cells 
(right panels) by flow cytometry. The number indicated in the upper right quadrant is the frequency of human CD4+CD25+ or CD4+CD25+CCR4+ 
cells (%). e PBMCs obtained on day 28 from MT-2-infected mice treated with PBS (black bar) or with TARC–PE38 (dotted bar) were also used to meas-
ure PVLs with quantitative PCR. The data are presented as copies/100 cells. These results are representative of two independent experiments
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complex [34, 40], reduction of CCR4+ cells by treatment 
with TARC-PE38 reflects disappearance of CCR4 but 
may not exactly reflect elimination of CCR4+ cells (the 
killing effect of TARC-PE38 on CCR4+ cells). Therefore, 
to evaluate the killing effect of TARC-PE38 on infected 
(CD4+CD25+CCR4+) cells accurately, we checked 
CD4+CD25+ cells rather than CCR4+ cells. In the MT-
2-infected mice treated with TARC–PE38, the increase 
in the frequency of HTLV-1-infected cells was markedly 
inhibited compared with that in the MT-2-infected mice 
treated with PBS (mean 5.48 vs 10.24 %, respectively, on 
day 21, and 8.88 vs 29.27 %, respectively, on day 28) and 
almost the same as that in the uninfected mice (8.22 % on 
day 28).
However, because in spite of TARC-induced inter-
nalization of CCR4, TARC-PE38 undergoes degradation 
after administration to mice in the humanized mouse 
model, the internalization of CCR4 is presumably not 
persistent during the long observation in vivo. Thus, data 
for CCR4+ cells in the humanized mouse model could be 
still important and supportive to evaluate the therapeutic 
effect of TARC-PE38, and indicated significant CCR4+ 
cell reduction by treatment with TARC-PE38 (Additional 
file  4: Figure S3). It was also demonstrated after day 28 
that a population of CD4+CD25+ cells (Fig. 3d, left pan-
els) or CD4+CD25+CCR4+ cells (Fig.  3d, right panels) 
completely disappeared by treatment with TARC-PE38, 
indicating that the treatment selectively targets CD25+ 
(infected) cells, not CD25− (uninfected) cells, especially 
among CCR4+ cells.
We also measured the PVLs with quantitative PCR in 
PBMCs collected on day 28 from each mouse treated 
with TARC–PE38 or PBS. Consistent with the above 
results, the PVLs (<10 copies/100 cells) in the PBMCs 
from mice treated with TARC–PE38 were significantly 
lower than those (around 30–90 copies/100 cells) in mice 
treated with PBS (Fig. 3e).
Thus, TARC–PE38 exerts a potent therapeutic effect on 
HTLV-1 infection in a humanized mouse model.
TARC–PE38 reduces PVLs in PBMCs from asymptomatic 
carriers
We also examined the therapeutic effect of TARC–PE38 
on primary HTLV-1-infected cells. Because in this study 
we mainly focused on the therapeutic potential of TARC-
PE38 to prevent the development of ATL for high-risk 
asymptomatic HTLV-1 carriers, not for ATL patients, we 
used PBMCs obtained from asymptomatic carriers alone 
in this experiment.
PBMCs obtained from seven asymptomatic carriers 
were incubated with 0 (PBS), 10, or 20  μg/ml TARC–
PE38 in the presence of interleukin 2 (IL2) for 5  days. 
The genomic DNA of the harvested PBMCs was then 
purified and used to measure the PVLs with quantitative 
PCR. Because of TARC-induced internalization of CCR4, 
reduction of CCR4+ cells by treatment with TARC-
PE38 may not exactly reflect elimination of CCR4+ cells 
(the killing effect of TARC-PE38 on CCR4+ cells) again. 
We therefore checked PVLs rather than CCR4+ cells to 
evaluate the killing effect of TARC-PE38 on infected cells 
accurately. As shown in Fig.  4, the PVLs all increased 
after the incubation as compared to those before the 
incubation. However, the PVLs in five of seven carriers 
tested definitely decreased after incubation with TARC–
PE38 compared with those after incubation with PBS, 
probably by killing HTLV-1-infected primary cells. This 
indicated that TARC–PE38 can effectively reduce the 
PVLs increasing during the active viral production.
Furin‑dependent cytotoxic effect of TARC–PE38 
on HTLV‑1‑infected cells
Because TARC–PE38 targets CCR4, it can attack nor-
mal CCR4+ cells. Thus, we compared a gene expression 
involved in the susceptibility to TARC–PE38 between 
HTLV-1-infected and uninfected CCR4+ cells.
Because full-length PE is cleaved within cells by the 
proprotein convertase, furin, which mediates its cytotox-
icity [35, 36], we investigated the expression of furin. If 
there were a difference in the intracellular expression of 
furin by HTLV-1-infected and uninfected CCR4+ cells, it 
may affect the killing effect of TARC–PE38 on these cells.
To examine whether the cytotoxic activity of TARC–
PE38 is mediated by the expression of furin, we tested 
whether a furin inhibitor blocked the killing effect of 
TARC–PE38 in the S1T cells. Whereas the cells incubated 
with TARC–PE38 alone were killed expectedly, the cells 
incubated with both TARC–PE38 and the furin inhibi-
tor grew well, at a similar rate to cells incubated with the 
furin inhibitor alone (Fig. 5a). Therefore, the furin inhibi-
tor definitely blocked the effect of TARC–PE38, even in 
the S1T cells which are most susceptible to TARC–PE38 
of all the cells tested (as shown in Fig. 1b, c), confirming 
that the effect of TARC–PE38 is furin-dependent.
Therefore, we quantified the expression of furin mRNA 
with quantitative RT–PCR in HTLV-1-infected S1T, 
TL-Om1, HUT-102, and MT-2 cells and in uninfected 
Jurkat cells, all CCR4+ cells (shown in Fig. 1a). The rela-
tive expression levels in the S1T, HUT-102, and MT-2 
cells were around four-, two-, and six-fold higher, respec-
tively, than that in the Jurkat cells, whereas that in the 
TL-Om1 cells was almost the same (Fig. 5b). These data 
indicated that most HTLV-1-infected cells express higher 
levels of furin than uninfected cells.
Regardless of the similar expression of the furin in 
TL-Om1 and Jurkat cells, TL-Om1 cells were clearly 
more susceptible to TARC-PE38 than Jurkat cells 
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(shown in Fig.  1b, c). This suggests that when the furin 
is expressed similarly, the susceptibility to TARC-PE38 
relies on the expression levels of CCR4 alone, as in fact 
those of CCR4 (MFI and/or percentage positive cells) 
were definitely higher in TL-Om1 cells than in Jurkat 
cells (shown in Fig. 1a).
Intracellular furin expression is increased by HTLV‑1 
infection/production
We then sought to clarify whether the intracellular 
expression of furin is enhanced by HTLV-1 infection. We 
compared two CCR4+ Jurkat-based cell lines, uninfected 
parental JET35 cells and HTLV-1-infected JEX22 cells 
which produce HTLV-1 upon stimulation with phorbol 
12-myristate 13-acetate (PMA)/ionomycin and express 
tdTomato (around 27 % positive when analyzed with flow 
cytometry), dependent on Tax expression. In these cells, 
we determined the frequencies of tdTomato-positive 
cells and the expression levels of furin mRNA with flow 
cytometry and quantitative RT–PCR, respectively, before 
and after the cells were stimulated. A flow-cytometric 
analysis showed that the JET35 and JEX22 cells expressed 
almost no tdTomato before stimulation. The stimulated 
JET35 cells were tdTomato-negative, whereas 98.4  % of 
the stimulated JEX22 cells were tdTomato-positive after 
sorting (Fig.  5c, upper panels). Quantitative RT–PCR 
showed the relative expression levels in each type of cell 
compared with that in Jurkat cells (Fig. 5c, lower panel). 
Interestingly, before stimulation, the expression of furin 
in HTLV-1-nonproducing JEX22 cells was almost the 
same as that in the JET35 cells (0.93 vs 1, respectively). 
However, after stimulation, the expression of furin in 
the HTLV-1-producing JEX22 cells (sorted above) was 
around two-fold higher than that in the JET35 cells (4.63 
vs 2.5, respectively). Also the expression of furin in the 
same stimulated JEX22 cells was around five-fold higher 
than that in the non-stimulated JET35 or JEX22 cells 
(4.63 vs 1 or 0.93, respectively). These data demonstrated 
that HTLV-1 infection/production enhances the intracel-
lular expression of furin.
To support this finding, we checked whether there 
was a positive correlation between PVLs and the expres-
sion of furin mRNA in PBMCs collected from 29 HTLV-
1-infected individuals (Additional file 5: Table S2). When 
PVLs and the expression of furin mRNA were measured 
in PBMCs with quantitative PCR and quantitative RT–
PCR, respectively, there was a clear positive correlation 
between them (R = 0.689, p < 0.0001) (Fig. 5d).
These results strongly suggest that TARC–PE38 elimi-
nates HTLV-1-infected CCR4+ cells more effectively than 
normal CCR4+ cells in a furin-expression-dependent 
manner.
Discussion
Approximately 20–30  % of asymptomatic carriers are 


































































































Fig. 4 Reduction in PVLs in PBMCs from asymptomatic carriers by TARC–PE38. PBMCs obtained from seven asymptomatic carriers (carriers #1–7) 
were incubated for 5 days in the absence (0 μg/ml, PBS only: blue line) or presence of 10 (green line) or 20 μg/ml TARC–PE38 (red line). The PVL in 
each culture was then measured with quantitative PCR. The data are presented as copies/100 cells. These results are representative of more than 
two independent experiments
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in Japan [13]. To block the development of ATL in this 
group, the PVL must be controlled. Therefore, in this 
study, we focused on HTLV-1-infected CCR4+ cells car-
rying the provirus, to develop a new antiviral agent.
A defucosylated humanized anti-CCR4 mAb, mogam-
ulizumab, was recently developed as a CCR4-targeting 
immunotherapy for ATL [25–30]. This study confirmed 
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R = 0.689 
(p < 0.0001)
tdTomato
Fig. 5 Furin-dependent activity of TARC–PE38 and increase in furin expression by HTLV-1 infection. a To test whether the effect of TARC–PE38 is 
dependent on furin expression, S1T cells were incubated with 500 ng/ml TARC–PE38 only (closed triangles), 500 ng/ml TARC–PE38 and a furin inhibi-
tor (open squares), or the furin inhibitor only (closed circles) for 4 days. The numbers of live cells were counted daily to assess cell viability. The data 
are presented as means ± SD (×105/ml). b Furin mRNA expression levels were measured with quantitative RT–PCR in HTLV-1-infected S1T, TL-Om1, 
HUT-102, and MT-2 cells and uninfected Jurkat cells. The data are presented as the expression level determined in each cell line relative to that in 
Jurkat cells. c The frequencies of tdTomato-positive cells in parental uninfected JET35 cells and HTLV-1-infected JEX22 cells before and 16 h after 
stimulation with PMA/ionomycin were analyzed with flow cytometry (upper panels) and the expression levels of furin were measured with quantita-
tive RT–PCR (lower panel). The frequency in stimulated JEX22 cells is presented as a percentage (%) and the expression level determined in each cell 
line is relative to that in Jurkat cells. As for the stimulated JEX22 cells, only tdTomato-positive HTLV-1-producing cells were isolated and used for the 
assays. d PBMCs obtained from 29 HTLV-1-infected individuals were used to examine the relationship between furin expression and PVLs. The furin 
mRNA expression levels and PVLs in these PBMCs were determined with quantitative RT–PCR and quantitative PCR, respectively. Each furin mRNA 
expression level is presented as the level determined in each sample relative to that in Jurkat cells. PVLs determined in the samples are presented as 
copies/100 cells. The correlation between the two parameters was then investigated statistically (R = 0.689, p < 0.0001)
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convincing and reliable. However, the anti-CCR4 mAb 
therapy induces several serious adverse effects, including 
Stevens–Johnson syndrome/toxic epidermal necrolysis, 
when normal CCR4+ Tregs are attacked [31–33].
As an “immunotoxin” (toxin fused to a ligand) [41–43] 
against ATL cells strongly expressing CD25 (IL2 recep-
tor α chain), anti-Tac (Fv)-PE38/LMB-2, in which the Fv 
portion of an anti-CD25 antibody is fused to PE38, has 
been developed by other investigators [44, 45], but its 
therapeutic effect on ATL was limited [44]. Therefore, we 
developed TARC–PE38 targeting CCR4 as a novel candi-
date anti-HTLV-1 drug.
When we examined the therapeutic effect of TARC–
PE38 on primary HTLV-1-infected cells, responders (car-
riers #1, 2, 3, 6, and 7) and non-responders (carriers #4 
and 5) to TARCPE38 could be clearly identified among 
the asymptomatic carriers. This difference in response 
to TARC-PE38 is probably, at least in part, due to the 
expression levels of CCR4 at the cell surface of PBMCs 
obtained.
TARC–PE38 has several major advantages. (1) 
Although the anti-CCR4 mAb functionally requires the 
ADCC activity mediated by NK cells, TARC–PE38 exerts 
a cytotoxic effect by itself, independent of ADCC activity. 
Therefore, TARC–PE38 can even be used in the absence 
of functional NK cells in immunocompromised hosts. (2) 
The anti-CCR4 mAb functions by binding to FcR on NK 
cells, but does not kill CCR4-expressing ATL cells uni-
formly in vitro, suggesting that the function of the anti-
CCR4 mAb may be affected by polymorphism of FcR 
[26]. In fact, FcR polymorphisms have been shown to 
impact the ADCC activity of other antibody-treatments 
[46, 47]. However, since TARC–PE38 does not need to 
bind to FcR to function, the function of TARC–PE38 is 
not affected by FcR polymorphisms. (3) The anti-CCR4 
mAb attacks normal CCR4+ cells in the same way as it 
attacks CCR4+ ATL cells, whereas TARC–PE38 seems 
to attack HTLV-1-infected CCR4+ cells more effec-
tively than it attacks normal CCR4+ cells. This advan-
tage depends on the upregulation of furin expression 
in the infected cells, and may enhance the therapeutic 
effect additively/synergistically while reducing the severe 
adverse effects of the CCR4-targeting therapy.
The PE38 protein is immunogenic in the human body. 
Because of this immunogenicity there is a limitation in 
doses given and repeated administrations of PE38-fused 
proteins to patients with normal immune systems. How-
ever, it was recently reported that silencing of T-cell 
epitopes in PE38 could diminish its immunogenicity [48]. 
Such a modification of PE38 would be very helpful in 
clinical applications of TARC-PE38.
The expression of the proprotein convertase, furin, is 
essential for the maintenance of the peripheral immune 
tolerance mediated by Tregs [49]. It has recently been 
reported that HTLV-1 primarily infects Tregs in patients 
with HTLV-1-associated myelopathy/tropical spastic 
paraparesis (HAM/TSP) [21]. Therefore, HTLV-1 may 
take advantage of furin to enhance Treg functions by the 
preferential infection and expansion of Tregs. This idea is 
supported by the results of this study, which demonstrate 
both enhanced furin expression in HTLV-1-infected cells 
and a positive correlation between furin mRNA expres-
sion and PVLs in HTLV-1-infected individuals. How-
ever, the molecular mechanism underlying the increase 
in furin expression during HTLV-1 infection remains to 
be clarified. The expression of furin is not elevated by the 
induced expression of HTLV-1 Tax in JPX-9 cells [50] 
(Additional file 6: Figure S4).
A recent study has also shown that furin mRNA expres-
sion in the peripheral blood correlates with chronic hepa-
titis B virus (HBV) infection, suggesting the participation 
of furin in Treg-mediated immune suppressive mecha-
nisms during HBV infection [51]. This supports our find-
ing that furin mRNA expression correlates with HTLV-1 
infection. These observations during HTLV-1 and HBV 
infections may reflect a common survival strategy of 
viruses, through furin-mediated Treg function, to avoid 
the human immune response to viral infection. Because 
furin is probably involved in processing the HTLV-1 
envelope glycoproteins [52], which play an important 
role in viral entry into host cells [53, 54], the enhanced 
expression of furin may also facilitate virus production.
Conclusions
In this study, we demonstrated the robust therapeu-
tic effects of TARC–PE38 on HTLV-1 infection in  vitro 
and in vivo. We also report that TARC–PE38 may func-
tion more efficiently against HTLV-1-infected cells than 
against normal cells through the proprotein-converting 
(toxin-cleavage) activity provided by the HTLV-1-induced 
increase in furin expression. Therefore, because the thera-
peutic effects of TARC–PE38 depend on the expression of 
both CCR4 and furin, the effects mediated by the expres-
sion of each of these proteins may be additive, synergistic, 
and/or compensative. Undoubtedly, the strong expression 
of these proteins in HTLV-1-infected cells should greatly 
enhance the efficacy of TARC–PE38. Collectively, our 
results indicate that TARC–PE38 is a useful and promis-
ing candidate therapeutic agent for controlling HTLV-1 
infection, and therefore has significant prophylactic 
potential in preventing the development of ATL in the 
high-risk asymptomatic carriers of HTLV-1.
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Methods
Cells
The Jurkat and Raji cells are HTLV-1-negative human 
T-cell and B-cell lines, respectively. The U937 and THP-1 
cells are HTLV-1-negative human monocytic cell lines. 
The S1T, TL-Om1, MT-2, and HUT-102 cells are HTLV-
1-infected human T-cell lines [55–58]. The JET35 cells 
are indicator Jurkat cells stably transfected with a plas-
mid encoding the tdTomato under the control of the Tax 
response element. The JEX22 cells are the JET35 cells 
infected with the HTLV-1 molecular clone pX1 MT-M 
[59]. When stimulated with 50  ng/ml PMA and 1  μM 
ionomycin for 16–24 h, The JEX22 cells produce HTLV-1 
and simultaneously express tdTomato in response to the 
Tax expression.
Human peripheral blood obtained from HTLV-1-in-
fected individuals including asymptomatic carriers was 
provided by JSPFAD. PBMCs were isolated from the 
blood with Ficoll–Histopaque (Sigma-Aldrich, St. Louis, 
MO, USA) density gradient centrifugation. To test the 
effect of TARC-PE38, these primary cells were incubated 
in the presence or absence of TARC-PE38, supplemented 
with 20  U/ml recombinant human IL2 (Shionogi Phar-
maceutical, Osaka, Japan) for 5 days.
All research protocols were approved by the Institu-
tional Review Boards of the National Institute of Infec-
tious Diseases (Tokyo, Japan) before the start of the study.
Mice
NOD/SCID IL2-receptor-γ-chain-knockout (NOG) and 
NOD/SCID Jak3-knockout (NOJ) mice were obtained 
from the Central Institute for Experimental Animals 
(Kawasaki, Japan) and Kumamoto University (Kuma-
moto, Japan), respectively [60, 61]. These mice were 
maintained under specific-pathogen-free conditions at 
the Animal Center of the National Institute of Infectious 
Diseases. Research protocols for the animal experiments 
were approved by the Animal Center and the ethics com-
mittee at the National Institute of Infectious Diseases, 
and they were performed according to institutional 
guidelines for the experimental use of animals.
Production of TARC‑fused recombinant proteins
The generation of TARC–PE38 and TARC-OFA, used as 
a control, has been described previously [34]. PE38 alone 
(without TARC) was produced as well.
Because TARC-PE38 has a tag at the C terminus to 
purify this protein, we also generated a different form of 
TARC-PE38, which the same tag is conjugated with at the 
N terminus to make the C terminus ending in REDL(K) 
or KDEL that is needed for the toxin activity of PE [62, 
63]. However, this form was not used in this study, due 
to its low activity relative to that of TARC-PE38 (data not 
shown).
Cell viability assay
Approximately 1 × 105 cells were seeded in each well of 
a 12-well plate. Different doses (0–20 μg/ml) of TARC–
PE38 were then added to the wells containing the target 
cells, in triplicate. As controls, other cells were treated in 
parallel with the same volume of PBS, the same doses of 
TARC–OFA, and/or the same doses of PE38 alone.
To determine whether the effect of TARC–PE38 is 
dependent on furin, a furin inhibitor (Furin Inhibitor I, 
Calbiochem, Billerica, MA, USA) (75 μM) was added to 
S1T cells seeded as described above in the presence or 
absence of TARC–PE38 (500  ng/ml). As an additional 
control, TARC–PE38 alone was added to the cells in 
parallel.
These mixtures were incubated for 4–5  days, and cell 
viability was quantified daily with the standard Trypan-
blue exclusion method by counting the number of live 
cells (×105/ml) in each well under a CK40 microscope 
(Olympus, Tokyo, Japan).
Flow‑cytometric analysis
In preparation for cell-surface staining, aliquots 
(~5 × 105) of cells were initially incubated with an FcR-
blocking reagent (Miltenyi Biotec, Gladbach, Germany) 
at 4  °C for 15  min. Cell lines were then stained with or 
without fluorescein isothiocyanate-labeled anti-CCR4 
antibody (R&D Systems, Minneapolis, MN, USA) at 4 °C 
for 30 min. PBMCs were incubated with or without fluo-
rescein isothiocyanate-labeled anti-human CD4 anti-
body, phycoerythrin-labeled anti-human CD25 antibody, 
and allophycocyanin-labeled anti-human CCR4 or CD45 
antibody (eBioscience, San Diego, CA, USA) at 4  °C for 
30 min.
The stained samples were fixed in 4  % paraformalde-
hyde (Wako, Osaka, Japan) and analyzed with a FACS-
Calibur flow cytometer using the CellQuest software (BD 
Pharmingen, Franklin Lakes, NJ, USA).
Quantitation of HTLV‑1 proviral load
To determine the PVL, the copy numbers of proviral 
DNA were measured with real-time PCR using the 7500 
Fast Real-Time PCR System (Applied Biosystems, Fos-
ter City, CA, USA). Genomic DNA (~200  ng) isolated 
from PBMCs with a QIAamp DNA Blood Mini Kit (Qia-
gen, Hilden, Germany) was used as the PCR template. 
Quantitative real-time PCR was performed in duplicate 
to amplify the pX region of the HTLV-1 provirus. The 
copy numbers of the human RNase P gene were meas-
ured in parallel as an internal control. The primers and 
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probe for RNase P were purchased from Applied Bio-
systems. Those for HTLV-1 pX were: forward primer 
pX2-S (5′-CGGATACCCAGTCTACGTGTT-3′), reverse 
primer pX2-AS (5′-CAGTAGGGCGTGACGATGTA-3′), 
and FAM-labeled pX2 probe (5′-CTGTGTACAAGGC 
GACTGGTGCC-3′) [64]. The copy number of pX in 
each sample was determined relative to that in TL-Om1 
cells. Finally, the PVLs of the tested cells were calculated 
as ([2  ×  copies of pX]/[copies of RNase P])  ×  100 and 
expressed as copies/100 cells.
Quantitation of furin expression
Quantitative real-time reverse transcription (RT)–PCR 
with the same system as described above was used to 
determine the mRNA levels of furin, in various cells. After 
JEX22 cells were stimulated for 16  h, tdTomato-positive 
cells were sorted with JSAN (Bay Bioscience, Kobe, Japan) 
and used. After total RNA was isolated from the cells 
and purified with Isogen (Wako, Osaka, Japan), quantita-
tive real-time RT–PCR was performed, in duplicate, to 
quantify both FURIN and GAPDH (internal control). The 
primer set for the FURIN was: forward primer 5′-TTCAC 
CAACACGTGGGCTG-3′ and reverse primer 5′-CGAT 
GCCAGAAGTGGTAATAGTCC-3′. The primer set for 
GAPDH was: forward primer 5′-ACCCACTCCTCCAC 
CTTTGA-3′ and reverse primer 5′-CTGTTGCTGTAGC 
CAAATTCGTT-3′. The furin mRNA level in each sample 
was calculated as 2−(Ct[furin]  −  Ct[GAPDH]) and expressed as 
the fold difference relative to that in Jurkat cells.
Administration of TARC–PE38 to a tumor‑bearing mouse 
model
Ten NOG mice were anesthetized with pentobarbital 
sodium (Kyoritsuseiyaku, Tokyo, Japan) and the postau-
ricular region of each mouse was inoculated subcutane-
ously with 2  ×  107 HUT-102 cells [39]. After the cells 
were grown for ~24 h, either 25 μg of TARC–PE38 per 
mouse or the same volume of PBS (control) was adminis-
tered to the same region in five mice per group daily for 
5 days. All the mice were sacrificed 2 weeks after inocu-
lation with the cells and the subcutaneous tumors were 
excised, weighed, and photographed with a standard dig-
ital camera (Fujifilm, Tokyo, Japan).
Establishment of humanized mice
Mononuclear cells were isolated from human cord blood 
(provided by Tokyo Cord Blood Bank, Tokyo, Japan) 
with Ficoll–Histopaque density gradient centrifuga-
tion. Human CD34+ hematopoietic stem cells (HSCs) 
were then purified with a Magnetic-Activated Cell Sort-
ing Direct CD34 Progenitor Cell Isolation Kit (Miltenyi 
Biotec), according to the manufacturer’s instructions. 
After the cells were enriched twice, more than 85  % of 
the HSCs obtained were CD34+. These cells (1–2 × 105 
cells per mouse) were immediately transplanted intrahe-
patically into newborn NOJ mice [61]. At about 3 months 
after transplantation, the frequency of human T cells in 
PBMCs was checked with flow cytometry to determine 
whether the mice were humanized.
Administration of TARC–PE38 to HTLV‑1‑infected 
humanized mice
Approximately 2  ×  107 MT-2 cells were treated with 
50  μg/ml MMC (Sigma-Aldrich) at 37  °C for 1  h. Six 
humanized mice were then inoculated intraperitoneally 
with ~2.5 × 106 MMC-treated cells per mouse and three 
control humanized mice were not inoculated. After 
2 weeks, either 10 μg of TARC–PE38 per mouse or the 
same volume of PBS (control) was administered intra-
venously every day for 4 days into three mice per group 
inoculated with MT-2 cells, and three control mice were 
untreated. PBMCs were isolated from all nine mice on 
days 0 (the day of inoculation with MT-2 cells), 14, 21, 
28, and later. The frequency of HTLV-1-infected cells 
and their PVLs were then tested with flow cytometry and 
quantitative PCR, respectively.
Statistical analysis
The data were expressed as means ± standard deviations 
(SD) for statistical analysis. Differences between groups 
were determined with Student’s t test. The correlation 
coefficient, R, was calculated with Spearman’s rank cor-
relation test to examine the correlation between two 
parameters. P  <  0.05 was considered significant. These 
analyses were performed using GraphPad Prism (Graph-
Pad Software, La Jolla, CA, USA).
Additional files
Additional file 1: Figure S1. Viability of MT-2 cells treated with MMC. 
After MT-2 cells were treated with 50 μg/ml MMC, they were cultured 
in vitro and the number of live cells was counted daily with the standard 
Trypan-blue exclusion method to check the viability of MT-2 cells. At three 
days post-MMC treatment most of the cells were dead.
Additional file 2: Figure S2. Phenotype of MT-2 cells. Expression of the 
indicated molecules on MT-2 cells was analyzed by flow cytometry. This 
analysis showed that MT-2 cells are CD45−CD3−CD4+CD8−. This phe-
notype of cells was analyzed similarly in samples from humanized mice 
inoculated with MT-2 cells and data obtained are shown in Additional 
file 3: Table S1.
Additional file 3: Table S1. Detection of MT-2 cells in humanized mice 
at 2 weeks post-inoculation with non- or MMC-treated MT-2 cells. Fre-
quencies of MT-2 cells and HTLV-1 PVLs were tested with flow cytometry 
and quantitative PCR, respectively, in splenocytes and PBMCs obtained 
from humanized mice at 2 weeks post-inoculation with non- or MMC-
treated MT-2 cells. In either mouse group MT-2 cells were not detected by 
flow cytometry (see Additional file 2: Figure S2 also). While the provirus 
was detected in splenocytes alone obtained from mice inoculated 
with non-treated MT-2 cells, it was not at all in splenocytes and PBMCs 
obtained from mice inoculated with MMC-treated MT-2 cells.
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